Thomson Reuters posts
FeedPosted Jun 26th 2009 11:00AM by Tom Johansmeyer (RSS feed)
Filed under: Pfizer (PFE), JPMorgan Chase (JPM), Goldman Sachs Group (GS), Morgan Stanley (MS)
Mergers and acquisitions aren't delivering the fees that investment bankers used to enjoy, but fortunately, the money's coming from elsewhere. Data from Thomson Reuters reports a 29% increase in capital markets and M&A fees for the first time in more than a year. Share sales (e.g., rights offerings) were where dealmakers found the action. In the shrinking M&A space, Morgan Stanley (NYSE: MS) has taken the lead spot.
Since there are fewer banks in the marketplace than there were a year ago -- and they have less money -- the capital is starting to come from elsewhere. Because they aren't lending at their previous pace, companies are issuing bonds and equity to replenish their coffers. Pfizer (NYSE: PFE), for example, raked in more than $23 billion from the bond market to fund its acquisition of Wyeth (NYSE: WYE), and Roche nabbed Genentech with the help of a $30 billion debt issuance.
Continue reading M&A plunges, investment banks find money elsewhere
Posted May 13th 2009 5:40PM by Jon Ogg (RSS feed)
Filed under: Earnings reports, Whole Foods Market (WFMI)
Whole Foods Market, Inc. (NASDAQ:
WFMI) reported its earnings at $0.19 non-GAAP EPS and $1.86 billion in revenues for the second quarter, and Thomson Reuters had consensus estimates of $0.18 EPS and $1.87 billion. The earnings included non-cash asset impairment charges of approximately $13 million, or $0.05 per share.
There are several things that are good about the quarter and there are a few issues. Same store sales were -4.1%, yet it showed operating cash flow of $173 million and generated $98 million of free cash flow. The company also maintained certain aspects of guidance, at least sort of. It sees opening two additional stores (including one relocation) in the third quarter and sees opening three stores in the fourth quarter, and is still waiting on the divestment approval from the FTC.
Continue reading Surprisingly, Whole Foods surges after earnings
Posted Nov 24th 2008 10:57AM by Laurie Pasternack (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Motorola (MOT), New York Times'A' (NYT), Analyst initiations, Rio Tinto plc ADS (RTP), Suntech Power Hldgs ADS (STP)
Analyst upgrades:
- Jefferies upgraded Buffalo Wild Wings (NASDAQ: BWLD) to Buy from Hold on valuation with the stock down 65% in two months as they believe the company has a "best-in-class fundamental story." The firm lowered its target to $25 from $30.
- Morgan Stanley upgraded Sanofi-Aventis (NYSE: SNY) to Overweight from Equal Weight on valuation and believes near-term cost reductions could provide a positive catalyst.
- Citigroup upgraded New York Times (NYSE: NYT) to Hold from Sell and lowered its target to $5.50 from $7 on valuation and believes the dividend cut will boost the company's liquidity.
- Pantry (NASDAQL PTRY) was upgraded to Outperform from Market Perform at Friedman Billings.
- LECG Corp (NASDAQ: XPRT) was raised to Buy from Neutral at UBS.
- Thomson Reuters (NYSE: TRI) was upgraded at RBC Capital to Outperform from Sector Perform.
Analyst downgrades:
- Jefferies downgraded Suntech (NYSE: STP) to Hold from Buy and lowered its target to $6 from $25 as they believe concerns about a convert refinancing in February 2010 will continue to weigh on the stock.
- Credit Suisse cut Ericsson (NASDAQ: ERIC) to Underperform from Outperform due to expectations for a decline in wireless infrastructure spending.
- ING downgraded shares of Rio Tinto (NYSE: RTP) to Hold from Buy as they believe it will be challenging for the company to execute asset sales planned at reducing debt in the current environment.
Continue reading Analyst calls: BWLD, SNY, NYT, STP, ERIC, RTP, KTOS, ZGEN
Posted Sep 22nd 2008 10:15AM by Laurie Pasternack (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, , Tyson Foods'A' (TSN), Analyst initiations, Teva Pharm Indus ADR (TEVA), Garmin Ltd (GRMN)
Analyst upgrades:
- Keefe Bruyette upgraded shares of AllianceBernstein (NYSE: AB) to Outperform from Market Perform as they find AB's risk/reward attractive given its attractive long-term business model. Wachovia upgraded Watson Pharma (NYSE: WPI) and Teva Pharma (NASDAQ: TEVA) to Outperform from Market Perform citing valuations and positive drivers for generics that include patent expirations and market share expansion.
- UBS raised Lloyds TSB Group (NYSE: LYG) to Neutral from Sell on expected pricing power following the HBOS (OTC: HBOOY) acquisition.
- Otter Tail (NASDAQ: OTTR) was upgraded to Outperform from Neutral at Baird.
- GFI Group (NASDAQ: GFIG) was upgraded at Citigroup to Hold from Sell.
- Merrill upgraded Logitech (NASDAQ: LOGI) to Neutral from Underperform.
Analyst downgrades:
- JP Morgan downgraded shares of Lloyds TSB Group to Underweight from Neutral on capital concerns and believes the HBOS acquisition is not in the best interest of shareholders.
- Stephens downgraded Universal Truckload (NASDAQ: UACL) to Equal Weight from Overweight on valuation and concerns about a slowdown in the flatbed sector. The firm's target remains $28.
Continue reading Analyst calls: AB, WPI, TEVA, LYG, UACL, NTAP, SIMO, BRCM ...
Posted Aug 16th 2008 9:40AM by Trey Thoelcke (RSS feed)
Filed under: Earnings reports, Sirius Satellite Radio (SIRI), Kohl's Corp (KSS), , Abercrombie and Fitch (ANF), Nordstrom, Inc (JWN)
Here are some highlights from this past week's earnings coverage from BloggingStocks:
Also, Jim Cramer warns against bearishness on the financials and also suggests that the collapse of commodities will buoy earings.
For more highlights from this week, see: Wal-Mart, JCPenney, MBIA, Deere, Applied Materials and others
Upcoming quarterly reports include Lowe's (NYSE: LOW), Home Depot (NYSE: HD), Hewlett-Packard (NYSE: HPQ), Target (NYSE: TGT), La-Z-Boy (NYSE: LZB), Saks (NYSE: SKS), BJ's Wholesale (NYSE: BJ), Limited Brands (NYSE: LTD), Barnes & Noble (NYSE: BKS), Burger King (NYSE: BKC), Gap (NYSE: GPS), Heinz (NYSE: HNZ), and Intuit (NASDAQ: INTU).
Visit AOL Money & Finance for more earnings coverage.
Posted Aug 12th 2008 3:22PM by Jonathan Berr (RSS feed)
Filed under: Earnings reports, Bad news, Competitive strategy, Thomson Reuters (TRI)
The timing of the Thomson-Reuters merger could not have been worse as many of their biggest customers on Wall Street are struggling. Now,
Thomson Reuters Corporation (NYSE:
TRI) is trying to make the best of a bad situation. Investors may
like what they are seeing today but they won't over the long term.
Shares of Thomson Reuters are trading up even though the financial information company reported disappointing earnings. The stock is rallying following an earlier sell-off. Revenue was $3.13 billion, a 73% rise but short of the $3.32 billion analysts surveyed by
Bloomberg News expected. The results benefited from the merger. Earnings were $172 million, or 22 cents per share, down from $375 million, or 58 cents per share a year earlier.
Chief Executive Tom Glocer told reporters that financial services markets "are likely to remain challenging through at least the end of the year." That means that big clients are going to be asking for big discounts. Bloomberg, my former employer and the company's biggest rival, has usually been able to resist this temptation.
Continue reading Thomson Reuters is in for a tough slog after missing expectations
Posted Apr 23rd 2008 12:10PM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst initiations
MOST NOTEWORTHY: Gen-Probe, iRobot and Emeritus were today's noteworthy initiations:
- RBC Capital expects Gen-Probe Inc. (NASDAQ: GPRO) to continue to generate high margin, annuity-like revenue from its core business while new tests with good long-term growth. Shares were initiated with an Outperform rating and $66 target.
- Kaufman Brothers believes robotics technology is more than just a fad and that iRobot (NASDAQ: IRBT) is well-positioned given its innovation applications and innovative applications that create new solutions to existing issues; Kaufman started iRobot with a Buy rating and $22 target.
- Jefferies believes Emeritus Corp. (AMEX: ESC), initiated with a Buy rating, is well-positioned to drive superior cash flow growth given favorable/stable industry fundamentals and renewed operational focus.
OTHER INITIATIONS:
Posted Apr 21st 2008 11:00AM by Laurie Pasternack (RSS feed)
Filed under: Analyst reports, Analyst initiations, Thomson Reuters (TRI),
MOST NOTEWORTHY: Full House Resorts, Starent Networks and Capital Trust were today's noteworthy initiations:
- Morgan Joseph said Full House Resorts Inc.'s (AMEX: FLL) valuation does not reflect the present value of its tribal management contract with the FireKeepers Casino. Shares were initiated with a Buy rating and $3.50 target.
- Starent Networks Corporation (NASDAQ: STAR) was assumed with an Overweight rating at Thomas Weisel. The firm said STAR offers a compelling risk/reward profile given strong gross margins and expanding operating margins.
- Keefe Bruyette initiated Capital Trust Inc. (NYSE: CT) with a Market Perform rating and $30 target, and believes the expected deterioration of commercial real estate fundamentals is likely to remain a headwind for valuations of the shares.
OTHER INITIATIONS:
Posted Apr 17th 2008 11:19AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst initiations
MOST NOTEWORTHY: Equitable Resources, Allied Capital and Apria Healthcare were today's noteworthy initiations:
- RBC Capital is positive on Equitable Resources' (NYSE:EQT) Appalachian Basin exposure and valuation. Shares were started with an Outperform rating and $78 target.
- Morgan Keegan views Allied Capital's (NYSE:ALD) valuation and outlook as attractive, starting shares with an Outperform rating.
Credit Suisse assumed Apria Healthcare (NYSE:AHG) with a Neutral rating and $20 target, citing the challenging Medicare backdrop.
OTHER INITIATIONS:
- Keefe Bruyette initiated Zions Bancorp (NASDAQ:ZION) with a Market Perform rating and $47 target.
- Thomson Reuters (NASDAQ:TRIN) was started with a Sell rating at ABN Amro.
- Canaccord Adams initiated Cyberonics (NASDAQ:CYBX) with a Buy rating and $20.50 target.